Tag Archives: Spero Therapeutics

SPR994:  A Long Shot, With Lots Of Twists And Turns To Phase III
May 23, 2019

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with

Leave a comment